ICCM,IceCure Medical Ltd | Healthcare

Healthcare

ICCM

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

IceCure Medical LtdICCM

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body.

It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Latest News >

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

Porch Group Reports Q2 Earnings, Higher Revenue; Full-Year Sales Outlook Increased

Aug 6, 2025

04:25 AM EDT, 08/06/2025 (MT Newswires) -- Porch Group ( PRCH ) reported Q2 earnings late Tuesday of $0.03 per share, swinging from a loss of $0.65 a year earlier. Analysts polled by FactSet expected a loss of $0.09. Revenue for the quarter ended June 30 was $119.3 million, compared with $110.8 million a year earlier. Analysts surveyed by FactSet...

Par Pacific Q2 Adjusted Earnings Rise, Revenue Falls

Aug 6, 2025

04:29 AM EDT, 08/06/2025 (MT Newswires) -- Par Pacific Holdings ( PARR ) reported Q2 adjusted earnings late Tuesday of $1.54 per diluted share, up from $0.49 a year earlier. Analysts surveyed by FactSet expected $0.90. Revenue for the quarter ended June 30 was $1.89 billion compared with $2.02 billion a year earlier. Analysts polled by FactSet expected $1.60 billion....

Israel's ICL second-quarter profit dips, sales rise

Aug 6, 2025

JERUSALEM, Aug 6 (Reuters) - Israeli potash and specialty chemicals producer ICL Group on Wednesday reported a dip in second-quarter profit, weighed down partly by Israel's war with Iran in June. ICL said it earned an adjusted 9 cents per diluted share in the second quarter, versus 10 cents a year earlier. Sales grew to $1.83 billion from $1.75 billion....